Evidence map›Paper›PMID 40604083›Full record

ArticleScientific reports2025

Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types.

Mahrukh Zakir, Alishbah Saddiqa, Mawara Sheikh, Lalarukh Zakir, Fatima Sami, Faisal Sardar Ahmad, Sadaf Abdul Rauf, Iqra Ali, Zahid Muneer, Wadi B Alonazi and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahrukh ZakirDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Alishbah SaddiqaDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Mawara SheikhPakistan Agriculture Research Council Islamabad, Islamabad, Pakistan.
Lalarukh ZakirAzad Jammu and Kashmir Medical College, Muzaffrabad, Pakistan.
Fatima SamiDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Faisal Sardar AhmadDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Sadaf Abdul RaufFatima Jinnah Women University, Rawalpindi, Pakistan.
Iqra AliDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Zahid MuneerDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan.
Wadi B AlonaziHealth Administration Department, College of Business Administration, King Saud University, PO. Box 71115, 11587, Riyadh, Saudi Arabia. waalonazi@ksu.edu.sa.
Abdul Rauf SiddiqiDepartment of Biosciences, COMSATS University, Park Road Islamabad, Islamabad, Pakistan. araufsiddiqi@comsats.edu.pk.

Funding

Dr Wadi B. Alonazi RSP2024R332
6 · The paper itself

Abstract

Breast cancer is the most prevalent and lethal form of cancer being the utmost common medical concern of women. Breast cancer etiology implicates numerous cellular protein receptors such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor/receptor 2 (HER2) which turn on oncogenic cascade often attributed to certain genetic variations. Breast Cancer is thus classified into ER + /-, PR + /-, HER2 ± and Triple Negative types. This study seeks to build upon our current knowledge of HER2 + and TNBC BC types to discover novel patterns for diagnosis and prognosis. The study exploits wealth of HER2 + and TNBC transcriptome (RNA Seq) data to elucidate the key hub genes, their associated networks, pathways, stage-wise expression profile, role in prognosis and survival expectancy, and regulatory transcription factors. The study also employs machine learning models including support vector machine (SVM), XGBoost, Random Forest, k nearest neighbor (kNN), Naïve Bayes and Voting Classifier to distinguish between HER2 + and TNBC transcriptomes which is a key variable for early detection and choice of therapeutic alternatives. RNA Seq datasets consisting of 49 HER2 + and 44 TNBC breast tumor samples were retrieved and pre-processed. Differentially Expressed Genes (DEGs) along with their logFC and p-values were fetched. The KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) analyses of DEGs were conducted on DAVID (the Database for Annotation, Visualization and Integrated Discovery) and interaction network was constructed through Cytoscape. Ten hub genes were obtained based on maximum clique centrality (MCC), maximum neighborhood component (MNC), degree, closeness and betweenness using cytoHubba which included ACTB, ATM, ESR1, GAPDH, HNRNPK, KRAS, MDM2, SIRT1, TP53, and H3F3C (H3-5). These hub genes were found to be associated with cell proliferation, invasion and migration. Transcription factors and association of the expression profile of these hub genes with survival expectancy was also determined. Among the ML models, SVM stood out, exhibiting classification success between HER2 + and TNBC transcriptomes with an accuracy of 90%. The findings of this study can therefore effectively aid in tracing the initial prognosis of BC and identify biomarkers for the personalized prevention, prediction, diagnosis, and treatment of BC.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPrognosisSupport Vector MachineTranscriptomeBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancer (BC)CytoHubbaCytoscapeDifferentially expressed genes (DEGs’)Expression analysisGene ontologyGEPIAHub genesHuman epidermal growth factor 2 (HER2 +)Machine learningNetwork analysisNetworkAnalyst and TIMERPathway analysisSurvival analysisTriple negative breast cancer (TNBC)UALCAN

Identifiers

PMID40604083
PMCPMC12222827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.